Article
HLA-DQ eplet mismatch load may identify kidney transplant patients eligible for tacrolimus withdrawal without donor-specific antibody formation after mesenchymal stromal cell therapy.
HLA - 1 Jul 2023
Bezstarosti Suzanne, Meziyerh Soufian, Reinders Marlies E J, Voogt-Bakker Kim, Groeneweg Koen E, Roelen Dave L, Kers Jesper, de Fijter Johan W, Heidt Sebastiaan
Abstract excerpt
Recently, the randomized phase-II Triton study demonstrated that mesenchymal stromal cell (MSC) therapy facilitated early tacrolimus withdrawal in living donor kidney transplant recipients. The current sub-study analyzed formation of de novo donor-specific HLA antibodies (dnDSA) in the context of the degree of HLA eplet mismatches. At the time of protocol biopsy at 6 months, 7/29 patients (24%) in the MSC group...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.